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Results: Proliferation of T cells when co-cultured with adenoviral-infected DC was
inhibited both in healthy volunteers (allogeneic response) and samples from PB
from children with JIA. However only minimal or no significant reduction in T cell
proliferation was seen when T cells were from the synovial fluid compartment.
The effect was not due to direct rAd infection of T cells.
Conclusions: We have shown that tolerogenic DC from synovial cells of children
with arthritis can be generated in vitro. These DC were able to inhibit T cell prolif-
eration when T cells were obtained from peripheral blood. Our data suggest that
T cells from the joint were resistant to this suppression. The mechanisms of this
resistance will be important to elucidate since this may provide new therapeutic
targets for childhood arthritis.
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Background: The presence of anti-CCP antibodies has been well established in
adult Rheumatoid Arthritis patients and children with JIA. Current commercial
ELISA kits use a reference ‘normal range’ derived from the adult population.
Anti-CCP antibody testing is not currently used for diagnosis of JIA given the low
sensitivity (reported detection rates of 4-10% in recent studies).
The aim of this study is to demonstrate whether using a paediatric normal range
for CCP and RF testing results in higher detection rates, which may increase the
value of these tests in a clinical setting.
Methods: Serum samples were collect from 43 patients with JIA and 26 juvenile
controls. Anti-CCP antibodies were detected using a combination of anti-CCP2
(Axis-Shield), anti-CCP3 (Inova) and an in-house peptide (cfc-1-cyc Invitrogen).
IgM RF and IgA RF were also measured in these samples by ELISA. The
manufacturer’s normal range was compared with a normal range calculated from
the 26 non-JIA controls (within 2 standard deviations from the mean).
Results: Measurement of anti-CCP2 antibodies in JIA identified 16% being positive
using the manufacturer’s normal range. Sensitivity was increased to 23% in this
assay using a normal range calculated from serum of juvenile controls. Using
a combination of all 3 assays, the detection rate of anti-CCP antibodies was also
23% when an adult normal range was applied. However, this increased to 33% if
the juvenile normal range was applied. 2 of the 26 juvenile controls tested positive
using the combined kits. Screening for RF isotypes IgM or IgA identified 11 out of
42 (26%) JIA patients. 20 out of 43 (47%) JIA patients had autoantibodies to either
anti-CCP or RF.
Conclusions: We have found that using a juvenile rather than an adult normal
range from age-matched controls increased the detection rate of anti-CCP
antibodies in JIA. This suggests that levels of anti-CCP antibody may change
with age. However, in order to prove this, a large scale study using appropriate
age-matched controls is needed.
At present, there is no single auto-antibody which is useful in diagnosing JIA.
We have demonstrated that combining RF with anti-CCP increased the serological
positivity to 47%. Therefore, screening for a combination of auto-antibodies may be
useful in diagnosing JIA.
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Background: Synovial fluid (SF) is a potential source of novel biomarkers for
many arthritic disorders involving joint inflammation, including Juvenile Idiopathic
Arthritis (JIA). We first compared the distinctive protein expression patterns of local
joint inflammation in SF with systemic profiles within matched plasma samples.
Preliminary investigations were performed into whether local or systemic proteome
‘fingerprints’ could distinguish between oligoarticular, extended oligoarticular and
polyarticular forms of this chronic juvenile disease.
Methods: In this study we analysed matched SF and plasma samples obtained
from 10 newly diagnosed JIA patients (<6 months disease duration): 3 with oligo-
articular arthritis, 3 extended oligoarticular and 4 polyarticular disease. Matched
samples were taken at the initial inflammatory episode. We profiled the SF and
plasma proteomes using a two-dimensional difference gel electrophoresis (DIGE)
approach. Progenesis PG240 software analysis of plasma and SF gel scans was
used to highlight joint-specific and plasma proteins differentially expressed across
the study group. Protein spots of interest were identified by matrix-assisted laser
desorption ionization (MALDI-TOF) and confirmed by nanoelectrospray-ionisation
mass spectrometry.
Results: 2D DIGE reveals 899 spots per gel within the pH 4–7 range for synovial
fluid and plasma. Comparison of plasma and synovial gel scans, revealed a sub-
population of 143 spots which predominate in synovial fluid or plasma. Hierarchical
clustering based on the expression levels of a set of 54 proteins with at least two
fold expression differences between the two body fluids segregates the synovial
fluid from the plasma samples. Proteolytic fragments of anti-inflammatory proteins
inter-alpha trypsin inhibitor, alpha-1 antitrypsin, transthyretin and apolipoprotein A-1
were identified. Principle component analysis of five different protein features could
be used to segregate patients into clinical subgroups.
Conclusions: Synovial fluid and plasma proteomes can be used to segregate a
heterogeneous group of JIA patients into clinical subgroups. Such an approach could
allow us to identify biomarkers useful in the prediction of disease progression, and
therefore enable earlier and more appropriate therapeutic intervention. Definition of
protein profiles which discriminate clinical subgroups of arthritic disease may assist
in the diagnosis of juvenile arthritis at an earlier stage than is currently possible.
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Background: Corticosteroid treatments, along with cytotoxic and disease modify-
ing agents, form the crux of the every day management of JSLE (Juvenile Systemic
Lupus Erythematosus). However this is not without significant side effects,
particularly in children. There are no randomised controlled trials investigating the
optimal steroid regime in JSLE and there is a paucity of evidence to draw upon,
even in adult studies.
Methods: On behalf of the UK JSLE Study Group we issued a standardised
questionnaire, designed to elucidate current practise in the prescription of steroids
during induction of remission and treatment of flare of JSLE, defined as a typical
child presenting with BILAG (British Isles Lupus Assessment Group) A disease.
This was sent to the lead paediatric rheumatologist & nephrologist in each UK
tertiary centre involved the UK JSLE Study Group.
Results: 18/26 (69%) questionnaires were returned (8 nephrology; 10 rheumatol-
ogy units) representing 13 centres.
Management of BILAG A at presentation:
All participants reported using pulsed intravenous methylprednisolone (IVMP)
as the steroid treatment of choice for induction of remission at presentation. The
most widely used dosing was 30 mg/kg (n¼11) or 600 mg/m2 (n¼ 4) for 3 doses.
The majority of clinicians (n¼ 14) gave repeated IVMP (variable intervals/duration).
17/18 reported using oral prednisolone in addition to the IVMP, the most widely
used doses being 60 mg/m2 (n¼5) or 1–2 mg/kg (n¼5). Weaning regime was
determined by time in 4 units while 13 units used clinical parameters including
reduction in BILAG, biomarkers, & physician’s clinical assessment. Weaning
regimes varied between all units. Ten units reported routine use of maintenance
steroids; the dose range was usually 5–10 mg. Personal experience was the main
rationale for treatment decisions.
Management of Disease Flare (to BILAG A):
In the treatment of flare of JSLE, 15 units reported using pulsed IVMP; 10 units
also increased oral prednisolone doses; 3 reported increasing oral prednisolone
dose alone. IVMP doses for flare were similar to those for induction of remission at
diagnosis, as was the weaning regime of oral prednisolone (wide variance noted
between clinicians) and use of maintenance steroids.
Conclusions: Steroid prescribing for acute JSLE varied widely between and within
units. As part of the UK JSLE Study Group, with an emerging clinical trials agenda,
it is vital to accrue an evidence base to direct steroid prescribing in the manage-
ment of JSLE acute presentation and flare. With paucity of evidence from the
literature, expert opinion (category D evidence) forms the main basis for current
treatment. We aim to carry this research forward and clinical trials to guide steroid
use in this setting are in development.
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Background: Hypermobility syndrome (HMS) is a major source of morbidity in
children. Due to pain, activities of daily living, physical and sports activities may be
limited in children with HMS (Murray and Woo 2001). However, this has not been well
documented. Ruperto et al (2004) reported that functional ability and physical and
psychosocial well-being of children with generalised joint laxity were not affected
when compared with healthy controls. Their study was conducted on children with
generalised joint laxity, however, and not those with HMS. Therefore, it is currently
unclear whether quality of life (QoL) in children with HMS is affected. This study
compared pain and QoL in children diagnosed with HMS with healthy controls.
Methods: Sixty-six children (29 diagnosed with HMS and 37 healthy children) aged
8–15 years participated in this study. Ethical approval was obtained for the study.
Informed written consent was obtained from the participants and their parents/
guardians. A diagnosis of HMS was established using the Beighton criteria
(Beighton et al 1973). The test knee was determined in healthy children using
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